Halozyme Therapeutics (HALO) Hits New 52-Week High at $19.44

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $19.44 and last traded at $18.14, with a volume of 663600 shares. The stock had previously closed at $18.16.

Several analysts recently issued reports on the company. BMO Capital Markets raised their target price on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a “market perform” rating in a research note on Wednesday, November 8th. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research note on Wednesday, September 27th. Barclays cut Halozyme Therapeutics from an “overweight” rating to a “hold” rating and raised their target price for the stock from $16.00 to $19.00 in a research note on Wednesday, November 22nd. BidaskClub raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Canaccord Genuity raised their target price on Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $18.13.

The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by ($0.04). The firm had revenue of $63.73 million for the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The business’s revenue was up 100.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.23) earnings per share. research analysts expect that Halozyme Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of HALO. Teacher Retirement System of Texas bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $129,000. Arrowstreet Capital Limited Partnership bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $131,000. Prudential Financial Inc. boosted its position in Halozyme Therapeutics by 8.7% during the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 940 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $171,000. Finally, Amalgamated Bank boosted its position in Halozyme Therapeutics by 5.3% during the 2nd quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 705 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3080254/halozyme-therapeutics-halo-hits-new-52-week-high-at-19-44.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.